Full-Time

Cdna – Commercial Analytics Manager

Cardiovascular

Confirmed live in the last 24 hours

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

Compensation Overview

$127k - $166.9k/yr

Mid, Senior

Thousand Oaks, CA, USA

Category
Project Management
Strategy Development
Strategy Research
Business & Strategy
Required Skills
Data Analysis
Requirements
  • Doctorate degree
  • Master’s degree and 2 years of analytics experience
  • Bachelor’s degree and 4 years of analytics experience
  • Associate's Degree and 8 years of analytics experience
  • High school diploma / GED and 10 years of analytics experience
Responsibilities
  • Design approach and perform secondary data analytics to support strategic decision-making
  • Lead analytical execution by implementing solutions, ensuring progress per timelines and scope, and coordinating readout of results
  • Work cross-functionally to synthesize findings, develop recommendations and articulate actionable insights to stakeholders
  • Provide senior leadership and brand teams with an objective and rigorous perspective on secondary data analytics and performance management
  • Develop and deliver analysis using complex data sources including hcp and account-level demand data, claims data, electronic medical records data, specialty pharmacy data, etc. to generate a holistic, objective, and detailed understanding of the brand
  • Manage relationship with external vendors to prioritize business needs and enable effective execution of analytics
  • Enhance the capabilities of the commercial data and analytics team by researching and implementing new analytical tools, methodologies, internal and external best practices, new data sources, etc.
Desired Qualifications
  • Familiar with technologies and applications, and hands-on experience to analyze, synthesize, and integrate various secondary data
  • Strong knowledge in data, analytics, research, and/or dashboarding & reporting approach
  • Capable to identify & define business problem, and address through data, analytics, and research
  • Proficient analysis and project management skills to turn unstructured business issues into action plans that result in meaningful strategic or tactical recommendations
  • Ability to drive implementation to enhance methodologies and standard processes
  • Strong Oral, Written presentation skills, with ability to explain complex concepts verbally or visually via ppt
  • Consistently engage and collaborate effectively with cross-functional team to shape brand strategy and understand risks and opportunities

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are derived from living organisms, to address conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The goal of Amgen is to improve patient care by providing effective therapeutic solutions and expanding its pipeline of potential new treatments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen's investment in AI aligns with trends in biotechnology innovation.
  • Institutional investments indicate strong market confidence in Amgen's growth.
  • FTC clearance of the Horizon merger may ease future regulatory hurdles.

What critics are saying

  • Competitors' AI-driven drug discovery could outpace Amgen's traditional R&D methods.
  • FTC scrutiny of mergers may complicate Amgen's future growth strategy.
  • Advancements in quantum technologies could pose a competitive threat to Amgen.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline of potential new therapies in development.
  • Amgen's acquisition of Horizon Therapeutics enhances its rare disease portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

BioSpace
Sep 19th, 2023
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans

The consent agreement struck between the FTC and Amgen and Horizon Therapeutics could have significant implications for ongoing and future M&A challenges, experts told BioSpace.